Start with the clinical goal

A treatment review looks at HbA1c, symptoms, cardiovascular disease, kidney function, heart failure, body weight, the risk of hypoglycaemia and your own preferences. Doctors choose many medicines for reasons other than weight loss. Some matter most for kidney or heart protection in defined groups. Others are there for glucose control. Current NICE guidance is a better starting point than a ranking of drugs on social media.

Metformin and SGLT2 inhibitors

Metformin and SGLT2 inhibitors work in different ways from GLP-1 receptor agonists. SGLT2 inhibitors make you pass more glucose in your urine and play an important part in heart and kidney care for suitable people. Their precautions differ too, with specific advice about illness and the risk of ketoacidosis. Taking a medicine by mouth does not put it in the same class as Rybelsus or Foundayo. Ask what benefit each medicine in your plan is meant to give.

DPP-4 inhibitors are a separate class

DPP-4 inhibitors act on the body's incretin system through a different mechanism from GLP-1 receptor agonists. They are not oral GLP-1 medicines. When you move between classes, your prescriber checks whether your current drugs still fit. A good review does not add every option on top. Keep your medication list accurate so anyone can spot duplicate or unneeded treatment.

Insulin may still be needed

GLP-1 medicines do not replace insulin in every case. Some people need insulin alongside them. Others need insulin because of symptoms or how high their glucose runs. MHRA reports of ketoacidosis after rapid insulin reduction show why any treatment change needs a plan. A smaller appetite or one good early glucose reading is no reason to stop insulin on your own.

Licence and NHS funding pathway are separate checks

A diabetes medicine may hold a licence without being the next recommended NHS option for you. Guidelines, local pathways and your own contraindications all shape access. Equally, obesity service rules do not apply automatically to an established diabetes indication. Ask your clinician which guideline and clinical factors drive the proposed change, especially if you first heard of the medicine through weight-loss marketing.

Make your next appointment count

Bring your current medicines, recent results, troublesome symptoms and practical barriers such as shift work or difficulty with injections. Ask what success looks like, which measurements your team will review and when you should seek help. A good plan also covers sick days and what to do if supply stops. Shared decisions work best when you understand the reason for every medicine, whatever the brand.

Know what each medicine is for

A combination makes more sense when each part has a clear purpose. One medicine may be there for glucose control and another for a specific heart or kidney benefit, with others treating blood pressure or cholesterol. Knowing this stops you assuming a new GLP-1 prescription makes the rest unnecessary. Ask what would prompt a review of each medicine, and whether any need different monitoring during illness, weight change or when you eat less. You should be able to follow the explanation without learning every drug class.

Sources

Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.

  1. NICE NG28: type 2 diabetes in adults nice.org.uk
  2. MHRA: GLP-1 medicines and rapid insulin reduction gov.uk
  3. Ozempic: UK prescribing information medicines.org.uk
  4. Rybelsus: UK prescribing information medicines.org.uk
  5. MHRA: UK approval of Foundayo gov.uk

Spotted something out of date? Report a mistake.